Personalizing the Path in mCRPC: Optimizing Chemotherapy and Aggressive Variant Prostate Cancer (AVPC) - Episode 5
Integrating Immunotherapy – Lessons from Small Cell Lung Cancer
A panel of experts discuss immunotherapy's potential role in complementing platinum-based chemotherapy for AVPC/NEPC based on small-cell lung cancer evidence, including the rationale for PD-1/PD-L1 combinations, the CHAMP trial investigating chemo-immunotherapy, limited efficacy of PD-1 monotherapy, and emerging bispecific T-cell engager options.
Panelists examine the rationale for incorporating immunotherapy into AVPC/NEPC treatment, drawing parallels to small-cell lung cancer where chemo-immunotherapy has demonstrated benefit. PD-1/PD-L1 inhibitors combined with platinum chemotherapy are discussed as a biologically plausible strategy, with the CHAMP trial highlighted as a key study evaluating this approach. The limited activity of PD-1 monotherapy in this population is acknowledged, reinforcing the need for combination strategies. Emerging immune-based approaches, including bispecific T-cell engagers, are presented as promising but investigational options.